AMRX|Amneal Pharmaceuticals, Inc.
Pharmaceutical Preparations
- Revenue
- $3.0B
- ▲ 8.0% YoY
- Operating margin
- 13.1%
- ▲ 46% YoY
- EBITDA
- $451M
- ▲ 45% YoY
- Market cap
- $22K
- Employees
- 8,500
- $355K revenue each
- Net debt / EBITDA
- 5.6×
- $2.5B net debt
- AI in 10-K
- 1.8
- mentions per 10K words
TSR below peersNo
—
3+ of last 5 years
High CEO pay despite TSRNo
—
Median CEO pay ≥ $15M while TSR trails
Earnings not backed by cashNo
472% of net income
Cash flow under 80% of net income
Dilutive SBCNo
1% of revenue
Over 10% of revenue
Payouts exceed cash flowNo
0% of cash flow
Buybacks + dividends over cash flow
Goodwill-heavyNo
16% of assets
Over 40% of assets
Shareholder dissentNo
100% lowest support
Any vote under 80% support
Buyer economics 0 of 4
Low revenue per employeeNo
$355K · 48th pct
Bottom quartile of its SIC industry
Quiet on AINo
1.8 per 10K words · 52nd pct
Bottom quartile of AI mentions in 10-Ks
Net cashNo
5.6× EBITDA net debt
More cash than debt, positive EBITDA
Buyout-sizedNo
$22K market cap
Market cap $500M–$5B
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY | Trend |
|---|
| Revenue | $2.1B | $2.2B | $2.4B | $2.8B | $3.0B | ▲ 8.0% | |
|---|
| Operating income | $153M | −$95M | $204M | $249M | $394M | ▲ 58% | |
|---|
| Net income | $13M | −$271M | −$84M | −$117M | $72M | ▲ 162% | |
|---|
| Operating cash flow | $242M | $65M | $346M | $295M | $340M | ▲ 15% | |
|---|
| Capex | $48M | $46M | $43M | $52M | $70M | ▲ 35% | |
|---|
| Stock-based comp | $28M | $32M | $27M | $28M | $32M | ▲ 15% | |
|---|
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|
| Aug 12, 2026 | Patel Tushar Bhikhubhai | SCHEDULE 13D/A | 17.6% | Passive |
| Aug 12, 2026 | Patel Chintu | SCHEDULE 13D/A | 9.4% | Passive |
| Aug 12, 2026 | Patel Chirag K. | SCHEDULE 13D/A | 8.4% | Passive |
| Mar 26, 2026 | Patel Dipan | SCHEDULE 13D/A | 5.4% | Passive |
| Oct 7, 2025 | Patel Chintu | SCHEDULE 13D/A | 8.2% | Passive |
| Oct 6, 2025 | Patel Dipan | SCHEDULE 13D/A | 7.6% | Passive |
| Aug 8, 2025 | Patel Chirag K. | SCHEDULE 13D/A | 7.1% | Passive |
| Mar 17, 2025 | Patel Tushar Bhikhubhai | SCHEDULE 13D/A | 15.7% | Passive |
| Jan 23, 2025 | Patel Dipan | SCHEDULE 13D/A | 7.7% | Passive |
| Oct 31, 2024 | Patel Chirag K. | SC 13D/A | 7.1% | Passive |
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $10M · 7
- Net
- −$10M
Pay vs performance
No pay-versus-performance disclosure yet.